drugset / Trial / NCT02233972

A Drug-Drug Interaction Study To Investigate The Ginkgolides Meglumine Injection To Alter The Pharmacokinetics Of Midazolam

NCT02233972

Phase 4 Completed 15 enrolled Jiangsu Kanion Pharmaceutical Co., Ltd
RandomizedParallel-groupOpen-labelBasic science

Summary

This is an open label, randomized, Parallel Assignment, placebo-controlled study. One of the purposes of this study is to investigate the multiple dosing Ginkgolides Meglumine Injection to alter the pharmacokinetics of Midazolam, the other is to calculate the pharmacokinetic parameters after Single and multiple dosing of Ginkgolides Meglumine Injection.

Timeline

Start
2014-08
Primary completion
2014-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ginkgolides Meglumine Unknown 25 mg Intravenous
Subject Midazolam Small molecule 7.5 mg

Indications

No indication recorded.